Neutrophil-to-lymphocyte ratio, blood eosinophils and COPD exacerbations: a cohort study.
Journal
ERJ open research
ISSN: 2312-0541
Titre abrégé: ERJ Open Res
Pays: England
ID NLM: 101671641
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
received:
19
07
2021
accepted:
24
10
2021
entrez:
6
1
2022
pubmed:
7
1
2022
medline:
7
1
2022
Statut:
epublish
Résumé
Blood neutrophil-to-lymphocyte ratio (NLR) and blood eosinophils (B-Eos) are emerging biomarkers in COPD. This study examined whether they could predict acute exacerbations of COPD (AECOPDs), and determined their longitudinal stability. In this closed cohort study, Swedish subjects with spirometry-verified COPD attended three yearly visits in a stable phase of the disease. Blood cell counts, spirometry and questionnaire-assessed AECOPD-history (worsening of COPD leading to an unscheduled visit and/or use of antibiotics and/or oral corticosteroids) were collected at each visit. Of 466 included subjects 57% were female. Baseline mean±sd forced expiratory volume in 1 s was 58±17% predicted. High NLR (≥3.0) was more common in subjects with previous AECOPDs than in those without (33.5% Stable phase NLR and B-Eos were associated with future AECOPDs. NLR on its own is probably not useful to predict AECOPDs but might be included in a risk scoring index. A minority of subjects with COPD had persistently elevated stable-phase NLR or B-Eos, and the biomarkers showed fair longitudinal reliability.
Sections du résumé
BACKGROUND
BACKGROUND
Blood neutrophil-to-lymphocyte ratio (NLR) and blood eosinophils (B-Eos) are emerging biomarkers in COPD. This study examined whether they could predict acute exacerbations of COPD (AECOPDs), and determined their longitudinal stability.
METHODS
METHODS
In this closed cohort study, Swedish subjects with spirometry-verified COPD attended three yearly visits in a stable phase of the disease. Blood cell counts, spirometry and questionnaire-assessed AECOPD-history (worsening of COPD leading to an unscheduled visit and/or use of antibiotics and/or oral corticosteroids) were collected at each visit.
RESULTS
RESULTS
Of 466 included subjects 57% were female. Baseline mean±sd forced expiratory volume in 1 s was 58±17% predicted. High NLR (≥3.0) was more common in subjects with previous AECOPDs than in those without (33.5%
CONCLUSIONS
CONCLUSIONS
Stable phase NLR and B-Eos were associated with future AECOPDs. NLR on its own is probably not useful to predict AECOPDs but might be included in a risk scoring index. A minority of subjects with COPD had persistently elevated stable-phase NLR or B-Eos, and the biomarkers showed fair longitudinal reliability.
Identifiants
pubmed: 34988219
doi: 10.1183/23120541.00471-2021
pii: 00471-2021
pmc: PMC8711083
pii:
doi:
Types de publication
Journal Article
Langues
eng
Informations de copyright
Copyright ©The authors 2021.
Déclaration de conflit d'intérêts
Conflict of interest: J. Ellingsen has received honoraria for lectures from AstraZeneca, Novartis and Teva; has served on advisory boards arranged by Novartis and GlaxoSmithKline and has received grants from Uppsala County Association against Heart and Lung Diseases and the Bror Hjerpstedt foundation. Conflict of interest: C. Janson reports no conflict of interest with regard to the present study. Conflict of interest: K. Bröms reports no conflict of interest with regard to the present study. Conflict of interest: K. Lisspers has received honoraria for lectures from AstraZeneca, Novartis, Boehringer Ingelheim and TEVA and served on advisory boards arranged by AstraZeneca, GlaxoSmithKline and Boehringer Ingelheim. Conflict of interest: B. Ställberg has received honoraria for educational activities and lectures from AstraZeneca, Boehringer Ingelheim, Meda/Mylan, Novartis, Chiesi and Teva, and has served on advisory boards arranged by AstraZeneca, Novartis, Meda, GlaxoSmithKline, Teva, and Boehringer Ingelheim, Conflict of interest: M. Högman reports no conflict of interest with regard to the present study. Conflict of interest: A. Malinovschi reports no conflict of interest with regard to the present study.
Références
Lancet. 2018 Nov 10;392(10159):1736-1788
pubmed: 30496103
J Cardiothorac Surg. 2019 Sep 11;14(1):164
pubmed: 31511078
Ups J Med Sci. 1986;91(3):299-310
pubmed: 3811032
Chest. 2002 Mar;121(3):688-96
pubmed: 11888946
Lancet Respir Med. 2019 Sep;7(9):745-756
pubmed: 31281061
J Chiropr Med. 2016 Jun;15(2):155-63
pubmed: 27330520
J Clin Med. 2019 Jul 02;8(7):
pubmed: 31269773
Am J Respir Crit Care Med. 2007 Sep 15;176(6):532-55
pubmed: 17507545
Respir Res. 2018 Jul 13;19(1):134
pubmed: 30001715
Am J Respir Crit Care Med. 2016 May 1;193(9):965-74
pubmed: 26641631
Int J Chron Obstruct Pulmon Dis. 2018 Jan 03;13:165-173
pubmed: 29379281
Eur Respir J. 2017 Nov 22;50(5):
pubmed: 29167301
N Engl J Med. 2019 Sep 12;381(11):1023-1034
pubmed: 31112385
Inflammation. 2014 Apr;37(2):374-80
pubmed: 24078279
Int J Chron Obstruct Pulmon Dis. 2021 Mar 18;16:701-713
pubmed: 33776429
BMC Pulm Med. 2018 May 2;18(1):65
pubmed: 29720140
Eur Respir J. 2018 Jul 27;52(1):
pubmed: 29724922
PLoS One. 2014 Nov 06;9(11):e112361
pubmed: 25375150
Allergy. 2019 Jul;74(7):1249-1256
pubmed: 30834543
COPD. 2017 Aug;14(4):382-388
pubmed: 28569614
PLoS One. 2016 Jun 03;11(6):e0156511
pubmed: 27258044
Int J Chron Obstruct Pulmon Dis. 2018 Nov 05;13:3651-3662
pubmed: 30464448
Pharmacoepidemiol Drug Saf. 2018 Nov;27(11):1191-1199
pubmed: 30264901
Int J Chron Obstruct Pulmon Dis. 2018 Sep 28;13:2999-3002
pubmed: 30319247
Korean J Intern Med. 2016 Sep;31(5):891-8
pubmed: 27017385
Tuberc Respir Dis (Seoul). 2020 Jul;83(3):185-194
pubmed: 32578413
Thorax. 2005 Nov;60(11):925-31
pubmed: 16055622
BMC Immunol. 2013 Aug 06;14:36
pubmed: 23919722
COPD. 2018 Apr;15(2):177-184
pubmed: 29558236
Bull Eur Physiopathol Respir. 1985 Nov-Dec;21(6):551-7
pubmed: 4074961
Eur J Clin Invest. 2018 Aug;48(8):e12984
pubmed: 29924383
Eur Respir J. 2016 May;47(5):1374-82
pubmed: 26917606
Am J Respir Crit Care Med. 2017 May 15;195(10):1402-1404
pubmed: 28165763
Lancet Respir Med. 2018 Feb;6(2):117-126
pubmed: 29331313
Eur Respir J. 2009 Sep;34(3):648-54
pubmed: 19720809
N Engl J Med. 2017 Oct 26;377(17):1613-1629
pubmed: 28893134
Am J Respir Crit Care Med. 2018 May 1;197(9):1216-1219
pubmed: 29035097
Medicine (Baltimore). 2019 Jul;98(28):e16371
pubmed: 31305434
Respir Res. 2020 Jan 10;21(1):15
pubmed: 31924207